Neumora submits IND for NMRA-215, reports dose data for NMRA-511
Neumora reported third-quarter 2026 results alongside an FDA IND submission for its NLRP3 inhibitor and new multiple ascending dose data for its vasopressin 1a receptor antagonist.
SEC filing